Riskpilot← Back to searchSign inGet full accessSCANDIDERMA AS
ASActiveOrg 895238902Stakkevollvegen 51, 9010 TromsøManufacture of basic pharmaceutical products · NACE 2110Est. 20100 employees
Revenue 2024
NOK 1,3M
+19% vs 2023
EBITDA margin
87.1%
+1679% vs 2023
Equity ratio
-1440.7%
Financial strength
Net profit 2024
NOK 1,2M
+659% vs 2023
| Revenue | NOK 1,3M | +19% |
| EBITDA | NOK 1,1M | +1679% |
| Net profit | NOK 1,2M | +659% |
| Total assets | NOK 416K | +2% |
| Equity | NOK -6M | +17% |
| Employees | 0 | — |
Legal name
SCANDIDERMA AS
Org number
895238902
Legal form
Aksjeselskap
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
2. mars 2010
Share capital
NOK 241 149
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Utvikle, produsere og selge kosmetiske ingredienser, samt engasjere seg i det som står i naturlig sammenheng med dette. Selskapet skal også kunne delta i andre selskaper med lignende økonomisk formål.
Address
Stakkevollvegen 51, 9010 Tromsø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 344 | 585 | 2 810 | 3 250 | 2 842 | 824 | 503 | 1 748 | 702 | 283 | 0 | 851 | 2 702 | 1 053 | 1 256 |
| Staff expenses | −194 | −437 | −1 025 | −1 208 | −593 | −201 | −0 | −506 | −61 | −579 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −139 | −258 | −1 402 | −1 113 | −268 | −829 | −2 956 | 1 166 | −110 | −570 | −726 | 311 | −607 | −69 | 1 093 |
| Depreciation & amort. | −0 | −0 | −96 | −286 | −433 | −433 | −433 | −433 | −433 | −433 | −433 | −433 | −338 | −147 | −0 |
| EBIT | −139 | −258 | −1 498 | −1 399 | −701 | −1 262 | −3 389 | 733 | −543 | −1 003 | −1 160 | −122 | −944 | −216 | 1 093 |
| Net financials | −0 | 81 | 20 | −6 | −4 | −19 | −403 | −312 | −291 | −319 | −445 | −458 | −4 | −0 | 114 |
| Profit before tax | −139 | −177 | −1 479 | −1 406 | −705 | −1 282 | −3 792 | 421 | −834 | −1 323 | −1 604 | −580 | −948 | −216 | 1 208 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −139 | −177 | −1 479 | −1 406 | −705 | −1 282 | −3 792 | 421 | −834 | −1 323 | −1 604 | −580 | −948 | −216 | 1 208 |
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 223 | 3 414 | 4 325 | 4 613 | 4 738 | 4 212 | 4 218 | 3 169 | 3 336 | 1 776 | 1 296 | 2 744 | 3 379 | 410 | 416 |
| Equity | −39 | 2 784 | 3 245 | 1 839 | 1 135 | 1 405 | −2 387 | −1 859 | −2 693 | −3 857 | −5 461 | −6 041 | −6 990 | −7 206 | −5 998 |
| Long-term debt | 0 | 333 | 810 | 1 731 | 2 815 | 1 698 | 2 966 | 3 435 | 4 153 | 4 389 | 5 275 | 5 836 | 5 118 | 5 048 | 5 054 |
| Short-term debt | 262 | 297 | 270 | 1 042 | 788 | 1 110 | 3 640 | 1 592 | 1 877 | 1 243 | 1 482 | 2 949 | 5 250 | 2 567 | 1 361 |
| Total debt | 262 | 630 | 1 080 | 2 774 | 3 603 | 2 808 | 6 606 | 5 028 | 6 029 | 5 632 | 6 757 | 8 785 | 10 368 | 7 616 | 6 415 |
EBITDA margin
87.1%
This company
15.8%
Market median
+451% vs market
20102024
Equity ratio
-1440.7%
This company
38.2%
Market median
-3871% vs market
20102024
Return on equity
120759200.0%
This company
18.4%
Market median
+656299900% vs market
20102024
Net profit margin
96.2%
This company
8.1%
Market median
+1088% vs market
20102024
Asset turnover
3.02×
This company
1.12×
Market median
+170% vs market
20102024
Debt / equity
1.07×
This company
0.62×
Market median
-73% vs market
20102024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ghk Invest As | Company | 35.3% | 35.3% | 2022 |
Kandal Invest As | Company | 19.2% | 19.2% | 2022 |
Seeberg Holding As | Company | 14.2% | 14.2% | 2022 |
Impeto As | Company | 6.0% | 6.0% | 2022 |
Montecristo Inv. International | Company | 5.0% | 5.0% | 2022 |
| Individual | 4.2% | 4.2% | 2022 | |
Jacek Bartosik | Company | 4.2% | 4.2% | 2022 |
R3 Holding As | Company | 2.1% | 2.1% | 2022 |
Drug Discovery Laboratory As | Company | 2.1% | 2.1% | 2022 |
Lavold Invest As | Company | 2.1% | 2.1% | 2022 |
| Individual | 1.9% | 1.9% | 2022 | |
Fimreite As | Company | 1.2% | 1.2% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Impeto As
SCANDIDERMA AS Board members of SCANDIDERMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kai-Hugo Hebnes | Board of Directors | 0 companies |
| Geir Håvard Kvalheim | Chairman | 0 companies |
| Carstein Seeberg | Board of Directors | 0 companies |
| Edel Margrete Kandal | Board of Directors | 0 companies |